Targeting Epstein-Barr Virus Super-Enhancer
Targeting Epstein-Barr Virus Super-Enhancer
批准号:
10379876
负责人:
Bo Zhao
金额:
$44.75万
依托单位国家:
美国
项目类别:
财政年份:
2016
资助国家:
美国
项目状态:
未结题
起止时间:
2016-03-01 至 2026-03-31
关键词:
AIDS-Related LymphomaAffectAutoimmune DiseasesB-LymphocytesBindingBinding SitesBiological AssayBiological ModelsBromodomainCRISPR screenCSPG6 geneCarcinomaCell LineCellsChIP-seqChromatinClustered Regularly Interspaced Short Palindromic RepeatsDNADNA BindingDNA MethylationDevelopmentDiseaseEBV-associated diseaseElementsEnhancersEpstein-Barr Virus InfectionsEpstein-Barr Virus Nuclear AntigensEpstein-Barr Virus-Related Malignant NeoplasmEpstein-Barr pathogenesisGene ExpressionGene ProteinsGenesGenetic TranscriptionGrowthHIVHealthHumanHuman Herpesvirus 4ImmuneImmunoprecipitationIn VitroInfectious MononucleosisInterventionKnock-outLinkLymphomaLymphoproliferative DisordersMalignant NeoplasmsMembrane ProteinsModelingMolecularNF-kappa BOncogenesOncogenicOncoproteinsPersonsProliferatingProteinsProteomicsQuantitative Reverse Transcriptase PCRRNARUNX3 geneReporterRestRheumatoid ArthritisRoleSPI1 geneSignal TransductionSiteTestingTherapeuticTherapeutic InterventionViral GenesViral Proteinsbasecohesindeep sequencingexperimental studygenetic manipulationgenome-wideinhibitorinsightknock-downlymphoblastlymphoblastoid cell linenovel therapeuticspost-transplantprogramssmall hairpin RNAtranscription factortumorigenesisvirus related canceryoung adult
中文摘要
EB病毒(EBV)引起传染性单核细胞增多症、淋巴瘤和淋巴增生性淋巴瘤。
艾滋病毒感染者和免疫抑制者的疾病,并与自身免疫性疾病有关。
EBV将静息B淋巴细胞(RBL)转化为持续增殖的淋巴母细胞
通过表达EBV核抗原(ENBA)和潜伏膜蛋白1(LMP 1)
能激活NF-κ B由于LCL表达与某些EBV癌症相同的EBV蛋白,
因此,将RBL转化为LCL是一种相关的模型,可以通过遗传操作,
研究EBV在生长转化中的作用。LCL增长取决于EBNA 2,EBNALP,
EBNA 3A、EBNA 3C和LMP 1。最近,我们发现所有必需的EBNA和LMP 1
激活的NF-κ B亚单位会聚到EBV超级增强子(ESE),
H3 K27 ac信号。ESE控制着驱动LCL生长的关键癌基因的表达,
对平均增强子的扰动更敏感。为了进一步表征
组成和他们的职能作用,在环境和社会经济,我们将(1)确定机制,通过
(2)确定ESE蛋白质组组成,并鉴定
决定ESE形成的蛋白质,和(3)确定ESE增强子的功能作用
RNA(eRNA)。我们将使用重复的规则间隔短回文重复序列(CRISPR)
用于鉴定ESE与其直接靶基因形成环所必需的DNA元件
和ESE活性所必需的蛋白质。我们将测试eRNA敲低对宿主的影响,
转录和成环因子DNA结合。这里的实验采用综合方法
阐明ESE激活关键致癌因子的分子机制。这些
研究将确定治疗干预的机会。
英文摘要
Epstein-Barr Virus (EBV) causes infectious mononucleosis, lymphomas and lymphoproliferative
diseases in HIV infected and immune suppressed people and is linked to autoimmune diseases.
EBV converts Resting B Lymphocytes (RBLs) to continuously proliferating Lymphoblasts Cell
Lines (LCLs) by expressing EBV nuclear antigens (ENBAs) and latent membrane protein 1 (LMP1)
that activates NF-kB. Since LCLs express that same EBV proteins as some EBV cancers, EBV
conversion of RBLs to LCLs is therefore a relevant model that can be genetically manipulated to
investigate EBV's role in growth transformation. LCL growth depends on EBNA2, EBNALP,
EBNA3A, EBNA3C and LMP1. Recently, we found that all the essential EBNAs and LMP1
activated NF-kB subunits converge to EBV super-enhancers (ESE) that have extraordinary
H3K27ac signals. ESEs govern the expression of key oncogenes that drive LCL growth and are
more sensitive to perturbations that average enhancers. To further characterize the molecular
composition and their functional roles in ESEs, we will (1) Determine the mechanisms through
which ESEs loop to their target genes, (2) Determine the ESE proteomic composition and identify
proteins that determine ESE formation, and (3) Determine the functional roles of ESE enhancer
RNA (eRNA). We will use Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)
based assays to identify the DNA elements essential for ESE to loop to their direct target genes
and proteins essential for ESE activity. We will test the effect of eRNA knock down on host
transcription and looping factor DNA binding. The experiments here in use integrative approaches
to elucidate the molecular mechanism by which ESEs activate key oncogenic divers. These
studies will identify opportunities for therapeutic intervention.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Molecular Mechanisms of Aminoglycoside Ototoxicity
-
批准号:10569609
-
项目类别:
-
资助金额:$55.41万
-
财政年份:2022
-
负责人:Bo Zhao
-
依托单位:
Molecular Mechanisms of Aminoglycoside Ototoxicity
-
批准号:10443277
-
项目类别:
-
资助金额:$56.87万
-
财政年份:2022
-
负责人:Bo Zhao
-
依托单位:
Optimized MR Fingerprinting for Rapid Volumetric Quantitative Neuroimaging
-
批准号:10266853
-
项目类别:
-
资助金额:$24.9万
-
财政年份:2020
-
负责人:Bo Zhao
-
依托单位:
Optimized MR Fingerprinting for Rapid Volumetric Quantitative Neuroimaging
-
批准号:10450170
-
项目类别:
-
资助金额:$24.9万
-
财政年份:2020
-
负责人:Bo Zhao
-
依托单位:
Optimized MR Fingerprinting for Rapid Volumetric Quantitative Neuroimaging
-
批准号:10260805
-
项目类别:
-
资助金额:$24.9万
-
财政年份:2020
-
负责人:Bo Zhao
-
依托单位:
Functions of Fam65b protein complex at the basal stereocilia in hearing and deafness
-
批准号:10194456
-
项目类别:
-
资助金额:$39.38万
-
财政年份:2018
-
负责人:Bo Zhao
-
依托单位:
Functions of Fam65b protein complex at the basal stereocilia in hearing and deafness
-
批准号:10433855
-
项目类别:
-
资助金额:$39.38万
-
财政年份:2018
-
负责人:Bo Zhao
-
依托单位:
Targeting Epstein-Barr Virus Super-Enhancer
-
批准号:9970995
-
项目类别:
-
资助金额:$44.75万
-
财政年份:2016
-
负责人:Bo Zhao
-
依托单位:
Fam65b function in hearing and deafness
-
批准号:9088059
-
项目类别:
-
资助金额:$25.24万
-
财政年份:2016
-
负责人:Bo Zhao
-
依托单位:
Targeting Epstein-Barr Virus Super-Enhancer
-
批准号:10596159
-
项目类别:
-
资助金额:$44.75万
-
财政年份:2016
-
负责人:Bo Zhao
-
依托单位:
Epstein-Barr Virus Nuclear Protein B Cell Growth Transformation
-
批准号:10219163
-
项目类别:
-
资助金额:$53.25万
-
财政年份:1987
-
负责人:Bo Zhao
-
依托单位:
Epstein-Barr Virus Nuclear Protein B Cell Growth Transformation
-
批准号:9977926
-
项目类别:
-
资助金额:$53.25万
-
财政年份:1987
-
负责人:Bo Zhao
-
依托单位:
海外基金